642 related articles for article (PubMed ID: 18024863)
1. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study.
Burger RA; Sill MW; Monk BJ; Greer BE; Sorosky JI
J Clin Oncol; 2007 Nov; 25(33):5165-71. PubMed ID: 18024863
[TBL] [Abstract][Full Text] [Related]
2. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer.
Cannistra SA; Matulonis UA; Penson RT; Hambleton J; Dupont J; Mackey H; Douglas J; Burger RA; Armstrong D; Wenham R; McGuire W
J Clin Oncol; 2007 Nov; 25(33):5180-6. PubMed ID: 18024865
[TBL] [Abstract][Full Text] [Related]
3. Phase II evaluation of imatinib mesylate in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group Study.
Schilder RJ; Sill MW; Lee RB; Shaw TJ; Senterman MK; Klein-Szanto AJ; Miner Z; Vanderhyden BC
J Clin Oncol; 2008 Jul; 26(20):3418-25. PubMed ID: 18612157
[TBL] [Abstract][Full Text] [Related]
4. Phase II trial of bevacizumab in the treatment of persistent or recurrent squamous cell carcinoma of the cervix: a gynecologic oncology group study.
Monk BJ; Sill MW; Burger RA; Gray HJ; Buekers TE; Roman LD
J Clin Oncol; 2009 Mar; 27(7):1069-74. PubMed ID: 19139430
[TBL] [Abstract][Full Text] [Related]
5. Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia.
Garcia AA; Hirte H; Fleming G; Yang D; Tsao-Wei DD; Roman L; Groshen S; Swenson S; Markland F; Gandara D; Scudder S; Morgan R; Chen H; Lenz HJ; Oza AM
J Clin Oncol; 2008 Jan; 26(1):76-82. PubMed ID: 18165643
[TBL] [Abstract][Full Text] [Related]
6. Phase II trial of bevacizumab in recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study.
Aghajanian C; Sill MW; Darcy KM; Greer B; McMeekin DS; Rose PG; Rotmensch J; Barnes MN; Hanjani P; Leslie KK
J Clin Oncol; 2011 Jun; 29(16):2259-65. PubMed ID: 21537039
[TBL] [Abstract][Full Text] [Related]
7. Phase II trial of combination bevacizumab and temsirolimus in the treatment of recurrent or persistent endometrial carcinoma: a Gynecologic Oncology Group study.
Alvarez EA; Brady WE; Walker JL; Rotmensch J; Zhou XC; Kendrick JE; Yamada SD; Schilder JM; Cohn DE; Harrison CR; Moore KN; Aghajanian C
Gynecol Oncol; 2013 Apr; 129(1):22-7. PubMed ID: 23262204
[TBL] [Abstract][Full Text] [Related]
8. A phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study.
Modesitt SC; Sill M; Hoffman JS; Bender DP;
Gynecol Oncol; 2008 May; 109(2):182-6. PubMed ID: 18295319
[TBL] [Abstract][Full Text] [Related]
9. Phase II study of bevacizumab and pemetrexed for recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal cancer.
Hagemann AR; Novetsky AP; Zighelboim I; Gao F; Massad LS; Thaker PH; Powell MA; Mutch DG; Wright JD
Gynecol Oncol; 2013 Dec; 131(3):535-40. PubMed ID: 24096113
[TBL] [Abstract][Full Text] [Related]
10. Predictive and prognostic angiogenic markers in a gynecologic oncology group phase II trial of bevacizumab in recurrent and persistent ovarian or peritoneal cancer.
Han ES; Burger RA; Darcy KM; Sill MW; Randall LM; Chase D; Parmakhtiar B; Monk BJ; Greer BE; Connelly P; Degeest K; Fruehauf JP
Gynecol Oncol; 2010 Dec; 119(3):484-90. PubMed ID: 20870280
[TBL] [Abstract][Full Text] [Related]
11. Bevacizumab toxicity in heavily pretreated recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancers.
Martin JY; Urban RR; Liao JB; Goff BA
J Gynecol Oncol; 2016 Sep; 27(5):e47. PubMed ID: 27329195
[TBL] [Abstract][Full Text] [Related]
12. A phase II study of a urokinase-derived peptide (A6) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma: a Gynecologic Oncology Group study.
Gold MA; Brady WE; Lankes HA; Rose PG; Kelley JL; De Geest K; Crispens MA; Resnick KE; Howell SB
Gynecol Oncol; 2012 Jun; 125(3):635-9. PubMed ID: 22446624
[TBL] [Abstract][Full Text] [Related]
13. Randomized phase II trial of bevacizumab plus everolimus versus bevacizumab alone for recurrent or persistent ovarian, fallopian tube or peritoneal carcinoma: An NRG oncology/gynecologic oncology group study.
Tew WP; Sill MW; Walker JL; Secord AA; Bonebrake AJ; Schilder JM; Stuckey A; Rice L; Tewari KS; Aghajanian CA
Gynecol Oncol; 2018 Nov; 151(2):257-263. PubMed ID: 30177462
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of thalidomide in recurrent epithelial ovarian and peritoneal carcinoma.
Chan JK; Manuel MR; Ciaravino G; Cheung MK; Husain A; Teng NN
Gynecol Oncol; 2006 Dec; 103(3):919-23. PubMed ID: 16828852
[TBL] [Abstract][Full Text] [Related]
15. Randomized Phase II Evaluation of Bevacizumab Versus Bevacizumab Plus Fosbretabulin in Recurrent Ovarian, Tubal, or Peritoneal Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study.
Monk BJ; Sill MW; Walker JL; Darus CJ; Sutton G; Tewari KS; Martin LP; Schilder JM; Coleman RL; Balkissoon J; Aghajanian C
J Clin Oncol; 2016 Jul; 34(19):2279-86. PubMed ID: 27217446
[TBL] [Abstract][Full Text] [Related]
16. A phase II evaluation of tirapazamine plus cisplatin in the treatment of recurrent platinum-sensitive ovarian or primary peritoneal cancer: a Gynecologic Oncology Group study.
Covens A; Blessing J; Bender D; Mannel R; Morgan M;
Gynecol Oncol; 2006 Mar; 100(3):586-90. PubMed ID: 16249022
[TBL] [Abstract][Full Text] [Related]
17. A phase II evaluation of AMG 102 (rilotumumab) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: a Gynecologic Oncology Group study.
Martin LP; Sill M; Shahin MS; Powell M; DiSilvestro P; Landrum LM; Gaillard SL; Goodheart MJ; Hoffman J; Schilder RJ
Gynecol Oncol; 2014 Mar; 132(3):526-30. PubMed ID: 24361733
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group.
Bookman MA; Darcy KM; Clarke-Pearson D; Boothby RA; Horowitz IR
J Clin Oncol; 2003 Jan; 21(2):283-90. PubMed ID: 12525520
[TBL] [Abstract][Full Text] [Related]
19. Avoiding bevacizumab related gastrointestinal toxicity for recurrent ovarian cancer by careful patient screening.
Simpkins F; Belinson JL; Rose PG
Gynecol Oncol; 2007 Oct; 107(1):118-23. PubMed ID: 17658587
[TBL] [Abstract][Full Text] [Related]
20. A phase II trial of paclitaxel poliglumex in recurrent or persistent ovarian or primary peritoneal cancer (EOC): a Gynecologic Oncology Group Study.
Sabbatini P; Sill MW; O'Malley D; Adler L; Secord AA;
Gynecol Oncol; 2008 Dec; 111(3):455-60. PubMed ID: 18829087
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
